A double blind, placebo-controlled, randomized clinical trial that breast milk derived Lactobacillus gasseri BNR17 mitigated diarrhea-dominant irritable bowel syndrome
- 주제(키워드) diarrhea-dominant IBS , Lactobacillus gasseri BNR17 , IBS-QOL , colon transit time , microbiota
- 주제(기타) Nutrition & Dietetics
- 설명문(일반) [Shin, Suk Pyo] Hallym Univ, Dept Gastroenterol, Sacred Hosp, Chunchon, South Korea; [Choi, Yoon Mi; Kim, Won Hee; Hong, Sung Pyo; Hahm, Ki Baik] CHA Univ, Digest Dis Ctr, Bundang Med Ctr, 59 Yatap Ro, Seongnam 13496, South Korea; [Park, Jong-Min; Hahm, Ki Baik] CHA Bio Complex CHA Canc Prevent Res Ctr, Pangyo 13488, North Korea; [Kim, Joohee; Kwon, Oran] Ewha Woman Univ, Dept Nutr Sci & Food Management, 52 Ewhayeodae Gil, Seoul 03760, South Korea; [Lee, Eun Hyun] Ajou Univ, Grad Sch Publ Hlth, Suwon 16499, South Korea
- 등재 SCIE, SCOPUS
- 발행기관 JOURNAL CLINICAL BIOCHEMISTRY & NUTRITION
- 발행년도 2018
- URI http://www.dcollection.net/handler/ewha/000000151653
- 본문언어 영어
- Published As http://dx.doi.org/10.3164/jcbn.17-73
초록/요약
The exact pathogenesis of diarrhea-dominant irritable bowel syndrome (IBS) is not known, but the abnormal microbiota of the gastrointestinal tract is considered to be one of the important contributing factors as in other gastrointestinal diseases such as inflammatory bowel disease, antibiotic-associated diarrhea, and colorectal cancer as well as systemic diseases. Though diverse trials of probiotics had been continued in the treatment of diarrhea-IBS, only a few proved by randomized clinical trial. To prove the efficacy of Lactobacillus gasseri BNR17 isolated from breast milk in patients with diarrhea-IBS, prospective, randomized, placebo controlled clinical trial was done including health related-quality of life analysis, colon transit time, and the changes of fecal micro-biota. BNR17 significantly improved the symptoms of diarrhea compared to control group. Health related-QOL analysis showed significant improvement of abdominal pain, distension, disturbed daily life, and mean defecation frequency with BNR17. On comparative CTT before and after BNR17, 6 out of 24 subjects showed significant correction of rapid colon transit pattern, while only 2 out of 24 in placebo (p < 0.01). Upon fecal microbiota analysis, BNR17 significantly increased B. fecalis, E. rectale, C. aerofaciens, F. prausnitzil and B. steroris. Conclusively, Lactobacillus gasseri BNR17 can be a potential probiotics to ameliorate diarrhea-IBS.
more